Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)

BACKGROUND: These studies assessed the efficacy and safety of fevipiprant, an oral antagonist of the prostaglandin D(2) (PGD(2)) receptor (DP(2)), compared with placebo when added to standard-of-care (SoC) asthma therapy in patients with uncontrolled asthma. METHODS: ZEAL-1 (NCT03215758) and ZEAL-2...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:EClinicalMedicine
Auteurs principaux: Castro, Mario, Kerwin, Edward, Miller, David, Pedinoff, Andrew, Sher, Lawrence, Cardenas, Pamela, Knorr, Barbara, Lawrence, David, Ossa, Diego, Wang, Wei, Maspero, Jorge F
Format: Artigo
Langue:Inglês
Publié: Elsevier 2021
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099656/
https://ncbi.nlm.nih.gov/pubmed/33997741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100847
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires